EP3685163A1 - Rapid predictive method for characterising the radiosensitivity and/or the risk of tissue toxicity of an individual to irradiation - Google Patents
Rapid predictive method for characterising the radiosensitivity and/or the risk of tissue toxicity of an individual to irradiationInfo
- Publication number
- EP3685163A1 EP3685163A1 EP18748969.5A EP18748969A EP3685163A1 EP 3685163 A1 EP3685163 A1 EP 3685163A1 EP 18748969 A EP18748969 A EP 18748969A EP 3685163 A1 EP3685163 A1 EP 3685163A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- patm
- expressed
- sample
- normalized
- total
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 67
- 231100000419 toxicity Toxicity 0.000 title description 3
- 230000001988 toxicity Effects 0.000 title description 2
- 102000002804 Ataxia Telangiectasia Mutated Proteins Human genes 0.000 claims abstract description 31
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 claims abstract description 31
- 210000004027 cell Anatomy 0.000 claims description 161
- 108090000623 proteins and genes Proteins 0.000 claims description 53
- 102000004169 proteins and genes Human genes 0.000 claims description 53
- 230000001086 cytosolic effect Effects 0.000 claims description 43
- 230000005865 ionizing radiation Effects 0.000 claims description 36
- 210000004698 lymphocyte Anatomy 0.000 claims description 36
- 230000001413 cellular effect Effects 0.000 claims description 32
- 210000002950 fibroblast Anatomy 0.000 claims description 28
- 210000004369 blood Anatomy 0.000 claims description 23
- 239000008280 blood Substances 0.000 claims description 23
- 238000001574 biopsy Methods 0.000 claims description 12
- 210000000601 blood cell Anatomy 0.000 claims description 9
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 238000012286 ELISA Assay Methods 0.000 claims description 2
- 230000001678 irradiating effect Effects 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000005855 radiation Effects 0.000 abstract description 6
- 239000000523 sample Substances 0.000 description 108
- 210000002307 prostate Anatomy 0.000 description 39
- 238000012360 testing method Methods 0.000 description 35
- 210000000481 breast Anatomy 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 17
- 238000002965 ELISA Methods 0.000 description 15
- 210000004940 nucleus Anatomy 0.000 description 13
- 230000008439 repair process Effects 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 11
- 210000000805 cytoplasm Anatomy 0.000 description 10
- 229920001917 Ficoll Polymers 0.000 description 9
- 238000001959 radiotherapy Methods 0.000 description 9
- 231100000987 absorbed dose Toxicity 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 238000005194 fractionation Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000005778 DNA damage Effects 0.000 description 4
- 231100000277 DNA damage Toxicity 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000528 statistical test Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000010219 correlation analysis Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000003439 radiotherapeutic effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000007390 skin biopsy Methods 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108700020463 BRCA1 Proteins 0.000 description 2
- 102000036365 BRCA1 Human genes 0.000 description 2
- 101150072950 BRCA1 gene Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000002661 proton therapy Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 206010001488 Aggression Diseases 0.000 description 1
- 108700040618 BRCA1 Genes Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 1
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102100034533 Histone H2AX Human genes 0.000 description 1
- 101001067891 Homo sapiens Histone H2AX Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 230000012361 double-strand break repair Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000005030 hippocampal neural stem cell Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010946 mechanistic model Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 238000001151 non-parametric statistical test Methods 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000693 radiobiological effect Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Definitions
- the invention relates to the field of medical radiobiology, and more particularly to the field of radiobiological laboratory methods.
- the present invention relates to a novel predictive method of cellular, tissue and clinical radiosensitivity based on the determination and cross-checking of a parameter and cellular and enzymatic criteria as well as a kit for predicting cell, tissue and clinical radiosensitivity. of an individual.
- tissue reaction such as a dermatitis or proctitis
- this tissue reaction is an indicator of a particularly high sensitivity of the patient to ionizing radiation.
- radiotherapy treatment even if interrupted at the time of the appearance of the first visible tissue signs, may increase the morbidity or even the post-treatment mortality of the patients, not only because the cancer it was supposed to treat was not able to be completely eradicated due to the premature termination of treatment, but also because of the collateral damage of healthy tissue induced by the radiation itself.
- ionizing radiation can break certain types of chemical bonds by generating free radicals (in particular by peroxidation) and other reactive species that cause DNA damage. Damage to DNA by endogenous or exogenous aggressions (such as ionizing radiation and free radicals) can lead to different types of DNA damage depending in particular on the deposited energy: base damage, single-strand breaks and double-strand breaks (DSBs).
- Unrepaired CBD is associated with cell death, toxicity and more specifically radiosensitivity.
- Badly repaired CBD is associated with genomic instability, mutagenicity, and susceptibility to cancer.
- the organization has repair systems specific to each type of DNA damage. For CBD, mammals have two primary modes of repair: suture repair (ligation of strands) and recombinant repair (insertion of a homologous or non-homologous strand).
- ATM and ATR Two proteins of the kinase family, commonly known as ATM and ATR, are known to be involved in the detection, repair and signaling of CBD; their action requires at least the presence of a protein known as the BRCA1 designation and an ordered phosphorylation cascade of the different ATM substrates (see the article by N. Foray et al., "A subset of ATM- and ATR-dependent phosphorylation events requires BRCA1 protein ", published in The EMBO Journal 22 (1 1), 2860-2871 (2003)). The test was undertaken to use the ATM enzyme in an explanatory model of cellular radiosensitivity (see Joubert et al., "DNA double-strand break repair defects in syndromes associated with acute radiation response" At least two different assays to predict intrinsic radiosensitivity?
- Radioresistant cells so-called Group I radiosensitivity
- moderately radiosensitive cells so-called Group II radiosensitivity
- extremely radiosensitive cells so-called Group III radiosensitivity
- the application WO 2015/121 596 A1 describes a predictive method for characterizing the radiosensitivity and the tissue reaction of a patient to therapeutic ionizing radiation. More particularly, this method includes the irradiation of a biological sample, the detection and quantification of radioinduced nuclear foci on fibroblastic-type connective tissue by the use of at least two detection markers among pH2AX, pATM and MRE1 1.
- the present invention aims to propose a new rapid, simple and reliable predictive method of individual radiosensitivity making it possible to screen individuals such as patients and guide them if the test is positive towards a more complete method of Tissue and clinical radiosensitivity.
- the pATM marker provides information on activation of the suture pathway by phosphorylation of H2AX and inhibition of the MRE1 pathway. dependent.
- the inventors have also found that the amount of pATM present in the basal state in the cytoplasm and the nucleus of a cell is a function of the cell type studied.
- the inventors have also found that the radiosensitivity status of an individual can be easily determined as a function of the amount of pATM present in the basal state in a cell of a given cell type, and this without this cell undergoes stress related to ionizing radiation inducing CBD within the cell. It is known that the efficiency and speed of DNA repair varies from one individual to another, and that there are also particular genetic conditions that lead to exceptional radiosensitivity.
- the problem is solved by a method based on: 1) detecting the amount of total, cytoplasmic and nuclear ATM protein; 2) a mechanistic model valid for human cells, especially blood cells; 3) functional tests regardless of the therapeutic modality.
- the inventors have discovered that the radiosensitivity of an individual can be predicted from non-irradiated cells.
- the inventors have discovered that the radiosensitivity of an individual can be predicted from cells taken from the blood of that individual.
- the inventors have discovered that the radiosensitivity of an individual can also be predicted from mucosal cells, epithelial cells, fibroblasts such as those present in the capillary bulbs, the epithelium of the inner face of the cheeks or from skin, said individual. Surprisingly, the inventors have discovered that the radiosensitivity of an individual can be predicted by a simple ELISA test without using foci counting techniques.
- the present method is applicable to the determination of radiosensitivity in relation to high doses as usually used in the treatment of cancers by ionizing radiation (electrons, photons, protons, particles) such as proton therapy or radiotherapy.
- ionizing radiation electrospray
- the absorbed doses are generally between 0.5 Gy and 6 Gy. This dose range typically corresponds to an individual session of radiotherapeutic treatment, the number of sessions depending on the location, type and stage of advancement. of the tumor.
- the dose for a radiotherapeutic treatment session is often of the order of 2 Gy.
- a first subject of the invention is a method for characterizing the radiosensitivity of an individual cell sample to ionizing radiation, said cell sample having been obtained from cells taken from said individual, said method being characterized in that the radiosensitivity is determined from the amount of ATM protein phosphorylated pATM in the basal state t 0 ,
- said method does not include irradiating said cell sample.
- an immunoenzymatic method such as an ELISA test, is used for the determination of the amount of the pATM protein.
- the amount of the activated pATM protein can be detected in the cytoplasm and the cell nucleus by an ELISA assay.
- the cell sample is selected from: a blood sample comprising lymphocytes or lymphoblasts, and a sample from a biopsy comprising fibroblasts.
- a second subject of the invention is a method for characterizing the radiosensitivity of a cellular sample of an individual to ionizing radiation said cellular sample having been obtained from cells taken from said individual, in which process
- target nucleated cells are isolated from the cell sample
- the radiosensitivity of the cell sample is determined using at least one parameter selected from the group consisting of the average number pATM to (normalized naked), the average number pATM to (standard cyto + nuc), the average number pATM to (normalized total), and the average number pATM L t o (normalized total)!
- pATM to (standard naked), expressed in ppm, denotes the average amount of pATM present in the nuclear compartment in the basal state t 0 expressed in ng divided by the total mass of cellular proteins extracted from said nuclear compartment expressed in ⁇ g;
- Patm l_to (normalized total), expressed as (ng / ml) / million cells refers average concentration Patm present in the cells in the basal condition t 0 expressed in ng / ml divided by the total number of cells.
- the total fractions or the cytoplasmic and nuclear fractions or the nuclear fractions of the cell sample are chosen in step (b) according to the parameter that it is desired to use in step (d) to determine the radiosensitivity of the cell. cell sample.
- the amount of the pATM phosphorylated ATM protein at base state t 0 determined in step (c) is calculated from , a parameter selected from the group consisting of the average number pATM to (normalized nude), the average number pATM t o (standard cyto + nuc), the average number pATM t o (normalized total), and the average number pATM L t0 (to standard tai) -
- the radiosensitivity of the cell sample is determined by comparing at least one parameter selected from the group formed by the average number pATM t o (normalized naked), the average number pATM t o (cyto + normalized nuc), the average number pATM to (normalized total), and the average number pATM L t0 (normalized total) to a threshold value Z, and we consider that the sample is: radioresistant if the selected parameter is greater than or equal to Z
- radiosensitive if the selected parameter is less than Z
- Z is a decimal or integer threshold value expressed in the same unit as that of the selected parameter.
- said target nucleated cells are chosen from: mucosal cells, epithelial cells, lymphoblasts, lymphocytes and fibroblasts, and even more preferentially from lymphoblasts, lymphocytes and fibroblasts.
- the radiosensitivity of a cell sample of an individual to ionizing radiation is determined on fibroblasts derived from biopsy of said individual and in which the sample is considered radio-resistant if pATM to (normalized naked) ⁇ B, it is considered that the sample is radiosensitive if pATM to (normalized nude) ⁇ B, where
- pATM to (standard naked), expressed in ppm, has the meaning indicated above, and B is an integer or decimal value between 1 x 10 -2 and 1 x 10 2 ppm.
- the radiosensitivity of a cell sample of an individual to ionizing radiation is determined on fibroblasts derived from biopsy of said individual and in which the sample is considered radio-resistant if pATM to (cyto + nuc normalized) ⁇ C, - the sample is considered radiosensitive if pATM to (cyto + normalized nuc) ⁇ C, where
- radiosensitivity of a cell sample of an individual to ionizing radiation is determined on biopsy fibroblasts of said individual and in which it is considered that the sample is radioresistant if pATM to (normalized total) ⁇ D, it is considered that the sample is radiosensitive if pATM to (normalized total) ⁇ D, where
- pATM to (standard total), expressed in ppm, has the meaning indicated above, and D is an integer or decimal value between 0.1 x 10 -1 and 5 x 10 2 ppm.
- the radiosensitivity of an individual's cell sample to ionizing radiation is determined on lymphoblasts and / or lymphocytes derived from blood cells of said individual and wherein the sample is considered radio-resistant if pATM to (normalized naked) ⁇ A, the sample is considered radiosensitive if pATM to (normalized naked) ⁇ A, where
- A represents an integer or decimal value of between 1 x 10 -2 and 5 x 10 2 ppm.
- the radiosensitivity of an individual cell sample to ionizing radiation is determined on lymphoblasts and / or lymphocytes derived from blood cells of said individual, preferably on lymphocytes derived from blood cells of said individual. and in which the sample is considered radio-resistant if pATM l_to (normalized total) ⁇ E, the sample is considered radiosensitive if pATM l_to (normalized total) ⁇ E, where
- pATM l_to (normalized total), expressed in (ng / ml) / million cells, has the meaning indicated above, and
- E represents an integer or decimal value of between 1 x 10 -2 and 5 x 10 2 (ng / ml) / million cells.
- a third object of the invention is a kit for characterizing the radiosensitivity of a cell sample of an individual to ionizing radiation, comprising:
- a fourth object of the invention is the use of this kit for determining the radiosensitivity, preferably the radiosensitivity status of a cellular sample of an individual to ionizing radiation.
- FIGS. 1 and 2 illustrate certain aspects of the invention, but do not limit its scope.
- Figure 1 shows a sensitivity / specificity curve (also called a ROC diagram of the English Receiver Operating Characteristics). This diagram makes it possible to evaluate the performance of a test by representing the rate of true positives (fraction of the individuals detected positive that are detected correctly by this test) as a function of the false positive rate (fraction of the individuals detected positive by this test then that they are actually negative).
- This diagram shows the performance of the prediction of the radiosensitivity of an individual evaluated from fibroblasts according to the ELISA method explained later where the sample is considered radio-resistant if pATM to (normalized normal) ⁇ B ppm or radiosensitive if pATM t o (normalized normal) ⁇ B ppm, with pATM t o (naked normalized), expressed in ppm, denoting the average amount of pATM present in the nuclear compartment in the basal state t 0 expressed in ng divided by the total mass of proteins cells extracted from said nuclear compartment expressed in ⁇ g and detected by ELISA.
- This B decimal value is thus between 1 x 10 -2 and 1 x 10 2 ppm.
- This threshold value B is fixed and is determined by the ROC curve (statistical tests in binary). depending on the number of true or false tolerated positives, ie depending on the desired sensitivity and specificity.
- FIG. 1 For a sensitivity of 0.68 and a specificity of 0.95, B is 7.6 ppm.
- Figure 2 shows the classification tree of the tested cell samples as a function of the pATM parameter t0 (normalized nuc ) and the threshold value B of 7.6 ppm.
- the classification approach used is based on the binary decision tree method (L. Breiman, J. Friedman, R. Olshen and C. Stone, "Classification and regression trees", Wadsworth & Brooks, 1984.).
- the threshold value B here 7.6 ppm
- the sample is considered radiosensitive and is classified in category 1.
- 26 are categorized as 0, i.e. radio-resistant and 14 are classified as radio-sensitive, i.e.
- FIG. 3 represents the histogram distribution of the tested cell samples as a function of the amount of pATM t0 (normalized nuc ) measured on the sample in ppm (ie average amount of pATM present in the nuclear compartment in the basal state).
- t 0 expressed in ng divided by the total mass of cellular proteins extracted from said nuclear compartment expressed in ⁇ g).
- the threshold value B for classifying the samples according to their radiosensitivity status as a function of the amount of pATM t o (normalized nuc) is represented on the histogram by a vertical bar at 7.6 ppm.
- the Wilcoxon test also called the Mann-Whitney U test or the Wilcoxon rank sum test
- the amount of pATM to (standardized cyto + nuc) measured on the cellular samples in ppm ie from Patm present in the cytoplasmic and nuclear compartments basal condition t 0 expressed in ng divided by the total weight of cellular proteins extracted from said cytoplasmic and nuclear compartments expressed in g
- the Wilcoxon test is a non-parametric statistical test to test the hypothesis that the distribution of data is the same for two groups, here for the two radiosensitivity states.
- results of this test are characterized by the probability p according to which the difference observed between the two groups, ie two radiosensitivity status is only due to chance.
- the probability p associated with this test is 0.001 and is relatively low indicating the existence of two distinct groups of data, ie two groups of radiosensitivity.
- the points present outside the uncertainty bars (°) are aberrant points.
- Figure 5 shows the variations in the proportion of pATM to (normalized naked) present in the cell nucleus of lymphoblasts from blood samples of patients GM03798, GM03380, GM07078, 37792 and 40479.
- FIG. 6 represents a matrix illustrating the correlations existing between the quantities of pATM present in the nucleus and the cell cytoplasm of lymphoblasts originating from blood samples of individuals in the basal state (0 Gy - non-irradiated state), after 5 min. and 10 min post irradiation at 2 Gy.
- 0Gy_nuc denotes the average amount of nuclear pATM present in the basal state t 0 , expressed in ppm.
- 5mnucu refers to the average amount of nuclear pATM observed in the nucleus 5 minutes after exposure of the cell sample to irradiation with a dose of 2 Gy. 5mnucu is expressed in ppm.
- 10mnucu means the average amount of nuclear pATM observed in the nucleus 10 minutes after exposure of the cell sample to irradiation with a dose of 2 Gy.
- Gy_cyto refers to the average amount of pATM present in the basal state t 0 in the cytoplasm of lymphoblasts, expressed in ppm.
- 5mn_cyto refers to the average amount of pATM observed in the cytoplasm of lymphoblasts 5 minutes after exposure of the cell sample to irradiation with a dose of 2 Gy.
- 5mn_cyto is expressed in ppm.
- 10mn_cyto refers to the average amount of pATM observed in the cytoplasm of lymphoblasts 10 minutes after exposure of the cell sample to irradiation with a dose of 2 Gy.
- 10mn_cyto is expressed in ppm.
- FIG. 7 represents a sensitivity / specificity curve (also called a Receiver Operating Characteristics (ROC) diagram). This diagram makes it possible to evaluate the performance of a test by representing the rate of true positives (fraction of the individuals detected positive that are detected correctly by this test) as a function of the false positive rate (fraction of the individuals detected positive by this test then that they are actually negative).
- ROC Receiver Operating Characteristics
- This diagram shows the performance of the prediction of the radiosensitivity of an individual evaluated from lymphocytes according to the ELISA method subsequently clarified where the sample is considered radioresistant if pATM Lto (total normalized) ⁇ E (ng / ml) / million cells or radiosensitive if pATM Lto (normalized total) ⁇ E (ng / ml) / million cells, with pATM Lto (total normalized), expressed in (ng / ml) / million cells, denoting the average concentration of pATM present in the cells at baseline t 0 expressed in ng / ml divided by the total number of cells.
- This E decimal value is thus 1 x 10 -2 and 5 x 10 2 (ng / ml) / million cells
- This threshold value E was fixed and determined by the ROC curve (statistical tests in binary) as a function of the number of true or tolerated false positives, ie, depending on the sensitivity and specificity desired, for an area under the curve (AUC of the English Area Under Curve) at 81% with a negative predictive value (abbreviated NPV).
- NPV negative predictive value
- PPV positive predictive value
- radioinduced damage all refer to ionizing radiation (as defined by IUPAC, known to those skilled in the art). ), and in particular to a particle-type radiation, such as consisting of particles of the proton, alpha (a) or beta ( ⁇ ) type, or else to a high energy electromagnetic radiation, in particular of the gamma ( ⁇ ) or X type. .
- nuclear compartment means the set of spaces of a nucleated cell delimited by a nuclear membrane and constituting the nucleus.
- cytoplasmic compartment means the set of spaces of a nucleated cell delimited by a cytoplasmic membrane and constituting the cytoplasm excluding the nuclear compartment.
- total fraction is understood to mean an extract of the cell sample obtained after total lysis containing all of the proteins of the cell, including nuclear and cytoplasmic proteins and more particularly pATM proteins.
- cytoplasmic fractions an extract of the cytoplasmic compartment of the cell sample obtained after subcellular fractionation, this extract containing cytoplasmic proteins including pATM proteins.
- nuclear fractions means an extract from the nuclear compartment of the cell sample obtained after subcellular fractionation, this extract containing nuclear proteins including pATM proteins.
- the method according to the invention uses at least one sample of healthy tissue, preferably fibroblasts or lymphoblasts / lymphocytes.
- the first are preferably taken from the connective tissue of an individual and the second from the blood. This sample can be taken by biopsy or blood sample.
- the operator takes from said individual a cell sample such as a sample blood cell comprising lymphoblasts or lymphocytes or a skin sample comprising fibroblasts.
- a cell sample such as a sample blood cell comprising lymphoblasts or lymphocytes or a skin sample comprising fibroblasts.
- the skin cell sample is generally taken by biopsy via the method of "dermatological punch" known to those skilled in the art.
- the cell sample is then placed in DMEM medium + 20% sterile fetal calf serum and then transferred without delay to a specialized laboratory, so that the sample does not remain for more than 38 hours at room temperature and is not altered.
- the cell sample from a biopsy can be used as is, upon receipt. It can also be established in the form of an amplifiable cell line according to a procedure that is well known in the culture laboratories and to those skilled in the art: by using in particular the tryptic dispersion (trypsination), the cells are again diluted in medium renewed and so on until the desired number of cells is obtained. After obtaining a sufficient number of cells (usually after one to three weeks), the first experiments are carried out using the method according to the invention. The cells are seeded on glass slides in petri dishes. These basal state fibroblasts thus obtained are then used as they are, without being irradiated (absorbed dose 0 Gy). - Blood sample
- the blood sample includes lymphoblasts or lymphocytes.
- the lymphocytes and / or lymphoblasts can be isolated by any appropriate means.
- the lymphocytes and / or lymphoblasts are preferably isolated from fresh whole blood via the technique of Ficoll ® known to those skilled in the art for more than 30 years and in particular described in the article by B0yum published in 1968 entitled “Isolation of mononuclear cells and granulocytes from human blood. "(Paper IV). Scand. J. Clin. Lab. Invest. 21 Suppl. 97, p.77-89.
- the separation of the blood components may be carried out by centrifugation on a cushion consisting of a copolymer of sucrose (sucrose) and epichlorohydrin, Ficoll ®. After centrifugation under appropriate conditions known to those skilled in the art, the constituents of the blood are separated by density. After removal of the supernatant containing the plasma and platelets, the lymphocytes and / or lymphoblasts are extracted from the cell sample and are then washed with at least one centrifugation / redispersion cycle in order to remove all traces of Ficoll ® , which is a toxic polymer for the cells.
- the thus purified lymphocytes are redispersed in a suitable culture medium, preferably in a RPMI 1640 culture medium provided by Gibco and comprising 10% fetal calf serum and 1% penicillin / streptomycin. These basal cell lymphocytes thus obtained are then used as they are, without being irradiated (absorbed dose 0 Gy).
- the biological material on which the experiments are carried out may be in particular lymphoblasts, isolated lymphocytes or cells isolated from tissue.
- the biological material is subjected to total lysis by any appropriate means.
- the lysis of the cells is carried out by the use of a RIPA lysis buffer (Thermofisher) according to the methodology described in the article by Kirby et al., "Adult hippocampal neural stem and progenitor cells regulate the neurogenic niche by VEGF secreting »Proc Natl Acad Sci USA 2015; (1 12): 13 p.4128-4133 or subcellular fractionation to recover total proteins or to extract and separate cytoplasmic proteins from nuclear proteins in the basal state.
- RIPA lysis buffer Thermofisher
- this fractionation is carried out by means of a kit (PIERCE) according to the methodology described for example in the article by Trotter and Archer, "Reconstitution of glucocorticoid receptor-dependent transcription in vivo", Molecular and Cellular Biology (2004).
- the cytoplasmic and nuclear fractions can be detected by immunoblotting tests also called "Western blot".
- Antibodies for detecting the presence of target proteins specific for each compartment are employed, such as anti-tubulin or anti-actin for the cytoplasmic compartment and anti-topoisomerase for the nuclear compartment.
- immunoblotting tests can then be performed on the protein mixtures contained in each of the isolated cytoplasmic and nuclear fractions in order to detect the presence of phosphorylated ATM proteins in each of the fractions.
- the phosphorylated ATM proteins are present in each of the cytoplasmic and nuclear fractions.
- the isolation and the capture of the phosphorylated ATM proteins in each of the total, cytoplasmic and nuclear fractions are carried out by any appropriate means, preferably by an ELISA test. 3. Quantification of pATM Proteins by ELISA Test:
- the isolation and the capture of the phosphorylated (and therefore active) ATM proteins in each of the total, cytoplasmic and / or nuclear fractions is carried out by TEST ELISA (Kit R & D Systems and Novateinbio) thanks to the use of plates coated with a specific antibody. anti-pATM (R & D Systems and Novateinbio).
- TEST ELISA Kinit R & D Systems and Novateinbio
- anti-pATM R & D Systems and Novateinbio
- the amount of pATM present is then analyzed by luminescence at 450 nm using a plate reader and the total amount of protein present is determined by a Bradford test known to those skilled in the art.
- This method has been implemented and validated on five lines of lymphoblasts, on human lymphocytes of 122 patients and 40 human fibroblast lines.
- the method according to the invention is based on the analysis of the kinase activity of the ATM protein present in the cell sample in the basal state studied, and more particularly on the quantification of the active ATM protein, ie the pATM marker. present in the nucleated cells of said sample, ie in the total, cytoplasmic and nuclear fractions of these cells in the basal state, ie unexposed (spontaneous state).
- the averages obtained for each point are computed with standard deviation errors of the mean (called "SEM") over a number of replicates greater than or equal to 2.
- SEM standard deviation errors of the mean
- pATM to (naked) denotes the average amount of nuclear pATM present in the basal state t 0 , expressed in ng.
- pATM to (standard naked) designates the average amount of pATM present in the nuclear compartment in the basal state t 0 expressed in ng detected by ELISA divided by the total mass of cellular proteins extracted from said nuclear compartment expressed in ⁇ g. pATM t o (normalized naked) is expressed in ppm.
- pATM to (cyto + nuc) refers to the average amount of pATM present in cytoplasmic and nuclear compartments in the basal state t 0 , expressed in ng.
- Patm to (cyto + nuc standardized) means the average amount of Patm present in the cytoplasmic and nuclear compartments basal condition t 0 expressed in ng detected by ELISA divided by the total weight of cellular proteins extracted from said cytoplasmic and nuclear compartments expressed in micrograms.
- pATM to (standard cyto + nuc) is expressed in ppm.
- Patm to (total) is the total average amount of Patm present either basal t 0 extracted from cells present in the analyzed sample, expressed in ng.
- pATM to (standard total) refers to the total average amount of pATM extracted from the cells expressed in ng divided by the total mass of proteins extracted from said cells expressed in ⁇ g.
- pATM t o (normalized total) is expressed in ppm.
- pATM l_to (normalized total) refers to the average concentration of pATM present in basal cells t 0 expressed in ng / ml divided by the total number of cells.
- pATM Uo (normalized total) is expressed in (ng / ml) / million cells.
- the parameters used are measured in basal condition t 0 and, preferably, by an ELISA.
- normalized parameters are calculated from the quantity of the phosphorylated protein ATM Patm to basal condition t 0 present in the cell sample.
- the normalized parameter pATM to (normalized normal), (respectively pATM to (standardized cyto + nuc)) is calculated from the amount of ATM phosphorylated pATM protein in the basal state t 0 present in the nuclear fractions (respectively in the cytoplasmic and nuclear fractions) of the cell sample.
- the normalized pATM to (normalized total) parameter is calculated from the amount of ATM phosphorylated pATM protein in the basal state t 0 present in the total fractions of the cell sample.
- the standardized pATM Lto parameter (normalized total) is calculated from the quantity (ie concentration) of the pATM phosphorylated ATM protein at basal state t 0 present in the total fractions of the cell sample. vs. Predictive evaluation
- the method according to the invention aims at the prediction of clinical parameters such as the radiosensitivity status from measured biological data, ie the amount of the active forms of the ATM protein in the cytoplasmic and nuclear compartments of nucleated cells given.
- This predictive evaluation results from a correlation between clinical data observed on cell lines such as the CTCAE grade and measured biological data.
- CTCAE Common Terminology Criteria for Adverse Events
- An adverse event is any adverse and unintended sign, symptom or illness temporally associated with the use of a medical treatment or procedure that may or may not be considered to be related to the treatment or medical procedure.
- An adverse event is a unique representation of a specific event used for medical documentation and scientific analysis.
- CTCAE classification provides a brief definition of each adverse event to clarify the meaning of the adverse event.
- This scale valid for other genotoxic stress (eg fire injury) is particularly used in radiotherapy.
- the grade refers to the severity of the adverse event.
- the CTCAE displays 5 severity grades (1 to 5) with unique clinical descriptions of severity for each adverse event and described in Table 1 below. Each grade of severity is defined by specific tissue reactions.
- Table 1 latest version of the CTCAE scale published by the National Cancer Institute of the United States of America on June 14, 2010 grade 1 Slight severity; asymptomatic or mild symptoms; clinical or diagnostic observations alone; intervention not indicated grade 2 Moderate severity; minimal intervention, local or noninvasive intervention indicated; event limiting the activities of daily life instrumented and adapted to the age (preparation of the meal, to do the shopping, use of the telephone %) grade 3 Serious severity or medically significant, but not immediately putting in danger; hospitalization or prolongation of the indicated hospitalization; disabling event; event limiting activities of care of daily life (baths, dressing, feeding, toilet use, taking medication, and not being bedridden) grade 4 Potentially life-threatening consequences; urgent intervention indicated grade 5 Death related to the adverse event
- the method according to the invention allows a qualitative diagnosis, which is directly derived from the mathematical value of scores or mathematical formulas using these scores.
- the radiosensitivity status can be determined on any type of nucleated cells and preferably on lymphocytes, lymphoblasts or fibroblasts.
- the method according to the invention makes it possible to characterize the radiosensitivity of a cellular sample of an individual to an ionizing radiation by comparing with a threshold value the amount of ATM protein phosphorylated pATM in the basal state t 0 .
- This method is binary insofar as it leads to the storage of cellular samples in two classes: “radiosensitive” and “radioresistant”. It is simple, easy to use and without irradiation of said cell sample; this significantly facilitates its use.
- the radiosensitivity of an individual cell sample to ionizing radiation is determined on lymphoblasts and / or lymphocytes derived from blood cells. of said individual as follows: the sample is considered radio-resistant if pATM to (normalized normal) ⁇ A is considered to be radiosensitive if pATM to (normalized nuci) ⁇ A where
- A is an integer or decimal value between 1 x 10 -2 and 5 x 10 2 ppm.
- the radiosensitivity of a cellular sample of an individual to ionizing radiation is determined on lymphoblasts and / or lymphocytes, preferably lymphocytes derived from blood cells of said individual, as follows: considers that the sample is radio-resistant if pATM Lto (normalized total) ⁇ It is considered that the sample is radiosensitive if pATM Lto (normalized total) ⁇ E where
- pATM Lto (normalized total) has the meaning given above in section 4b, and E is an integer or decimal value between 1 x 10 -2 and 5 x 10 2 (ng / ml) / million cells.
- the radiosensitivity status can be determined according to pATM to (standard nude) or pATM Lto (normalized total) -
- pATM to (standard nude) or pATM Lto (normalized total) -
- pATM Lto normalized total
- the threshold value A was determined by a correlation analysis of the discriminant values.
- the threshold value E was determined by a correlation analysis of the discriminant values.
- the radiosensitivity status of an individual is determined from a skin sample of said individual based on a threshold value expressed in relative value in parts per million (ppm).
- the radiosensitivity of a cellular sample of an individual to an ionizing radiation is determined on fibroblasts resulting from a skin biopsy of said individual in the following manner: it is considered that the sample is radioresistant if pATM to (normalized N) It is considered that the sample is radiosensitive if pATM to (normalized normal) ⁇ B
- B is an integer or decimal value between 1 x 10 -2 and 1 x 10 2 ppm.
- This threshold value B is fixed and is determined by the ROC curve (statistical tests in binary) according to the number of true or false positive tolerated, ie according to the desired sensitivity and specificity. For a sensitivity of 0.68 and a specificity of 0.95, B is 7.6 ppm (see Figures 1 and 2).
- Figure 2 shows the classification tree for 40 cell samples tested as a function of the pATM to (normalized nude) parameter and the B threshold value of 7.6 ppm (see Figure 3).
- the radiosensitivity of a cellular sample of an individual to an ionizing radiation is determined on fibroblasts resulting from a skin biopsy of said individual in the following manner: the sample is considered to be radio-resistant if pATM to (cyto + normalized nuc) ⁇ C - the sample is considered radiosensitive if pATM to (cyto + normalized nuc) ⁇ C where
- pATM to (standard cyto + nuc) has the meaning given above in section 4b, and C is an integer or decimal value between 1 x10 "2 and 1 x 10 2 ppm
- the radiosensitivity of a cellular sample of an individual to an ionizing radiation is determined on fibroblasts resulting from a skin biopsy of said individual in the following manner: the sample is considered to be radio-resistant if pATM to (normalized total) ⁇ D is considered to be radiosensitive if pATM to (normalized total) ⁇ D where
- pATM to (normalized total) has the meaning given above in section 4b, and
- D is an integer or decimal value between 0.1 x 10 -1 and 5 x 10 2 ppm.
- the threshold values B and C are fixed and are determined by the curve ROC (statistical tests in binary) ( Figure 1) which makes it possible to evaluate the performance of this test by representing the rate of true positives (fraction of the individuals detected positive which are detected correctly by this test) according to the rate of false positives (fraction of the individuals detected positive by this test whereas they are actually negative) ( Figure 2).
- the threshold value D is determined by deducting the other two threshold values B and C.
- the level of some single parameters such as pATM t o (nude normalized) or pATM L t0 (normalized total) is sufficient to establish a score and a diagnosis. 5. Predictive Evaluation of Radiosensitivity Status from a Cell Sample Using a Kit According to the Invention
- kits according to the invention can be used to characterize the radiosensitivity of a cellular sample of an individual to ionizing radiation.
- This kit comprises a) means for extracting the total fractions of the cell sample, i.e. reagents such as a lysis buffer known to those skilled in the art,
- the invention is illustrated below by examples which, however, do not limit the invention. These examples relate to the analysis of cell lines of individuals for determining the radiosensitivity status to which the individual belongs.
- lymphocytes were isolated from fresh whole blood via the Ficoll ® technique described previously. The separation of the constituents of the blood was obtained by centrifugation on a cushion of Ficoll ® (carbohydrate polymer of high molar mass). After centrifugation for 20 min at 400 g at room temperature, the blood constituents were separated by density. After removing the supernatant containing the plasma and platelets, lymphocytes were extracted from the cell sample, and then were washed in 1 x PBS and recentrifuged under the same conditions, so as to remove all traces of Ficoll ®. After removing the supernatant containing the Ficoll ®, the thus purified lymphocytes were redispersed in 1X PBS.
- Ficoll ® carbohydrate polymer of high molar mass
- Lymphocytes in the basal state were thus obtained and were then used as such, without being irradiated (absorbed dose 0 Gy).
- a cell sample of skin of an individual was taken by biopsy via the method of "dermatological punch".
- the cell sample was then placed in DMEM medium + 20% sterile fetal calf serum.
- the cell sample was then established as an amplifiable cell line.
- the cells were then diluted again in renewed medium and so on until the desired number of cells was obtained.
- the first experiments were carried out using the method according to the invention.
- the cells thus obtained, i.e. the fibroblasts were then used as such, without being irradiated (absorbed dose 0 Gy).
- Subcellular fractionation to separate cytoplasmic pATM proteins from nuclear pATM proteins was performed on cultured fibroblasts from the individual skin cell sample and lymphocytes from the above-mentioned individual blood sample. This fractionation was carried out using the PIERCE NE-PER nuclear and cytoplasmic extraction kit according to the manufacturer's protocol and the methodology described in the article by Trotter, KW and Archer, TK, Molecular and Cellular Biology (2004). Reconstitution of glucocorticoid receptor- depend on in vivo transcription.
- the amount of phosphorylated forms of ATM proteins (pATM) was measured on the cells cultured and fractionated, depending on the cell type studied. The amount of pATM protein was thus measured in each of the cytoplasmic and nuclear fractions of cultured fibroblasts resulting from the skin cell sample of the individual and in each of the cytoplasmic and nuclear fractions of the lymphocytes derived from the blood sample of the individual.
- cytoplasmic and nuclear fractions 50 ⁇ were collected and placed in a well of a plate coated with a specific anti-pATM antibody (R & D Systems and Novateinbio). In each well, the amount of pATM present was then analyzed by luminescence at 450 nm using a plate reader and the total amount of protein was determined by a Bradford test known to those skilled in the art.
- a specific anti-pATM antibody R & D Systems and Novateinbio
- Table 4 Quantities of the nuclear pATM protein (pATM to (normalized naked)) present in lymphoblasts from patients in the basal state
- pATM to (standard naked) has the meaning given above in section 4b.
- pATM to (normalized naked) is expressed in ppm.
- Patients 40479 and 37792 show mutations in the BRCA1 gene inducing a tendency to develop breast or ovarian cancers.
- the lymphoblast lines GM07078, 40479 and 37792 correspond to patients for whom the CTCAE grades are known.
- the clinically determined radiosensitivity status corresponds to that determined by the method according to the invention as a function of the relative amount of pATM to (normalized naked) and the threshold value A .
- the sample is considered to be:
- - A is an integer or decimal value between 1x10 "2 and 5x10 2 ppm Considering these threshold values, patient GM03798 is considered radioresistant and patients GM03380, GM07078, 37792 and 40479 are considered radiosensitive. shows the variations in the proportions of pATM in the nucleus in the basal state for these patients.
- the clinically determined radiosensitivity status corresponds to that determined by the method according to the invention as a function of the relative amount of pATM LTO. (normalized total) and threshold value E.
- the sample is considered to be:
- E is an integer or decimal value between 1 ⁇ 10 -2 and 5 ⁇ 10 2 (ng / ml) / million cells).
- CRM-00244 4.28 1 prostate + CRM-00246 1 1.6 2 ENT
- CRM-00262 9.25 1 anal channel +
- CRM-00284 18.7 2 breast CRM-00285 23.6 1 lung +
- ENT means a location within the Otorhinolaryngology sector.
- lymphoblasts were isolated from fresh whole blood via the Ficoll ® technique described previously. Lymphocytes in the basal state were thus obtained. A part of these lymphoblasts was then used as is, without the lymphoblasts being irradiated (absorbed dose 0 Gy - basal state) and a part of these lymphoblasts was irradiated on a medical irradiator according to a certified dosimetry with an absorbed dose D of 2 Gy. The irradiation was carried out with a medical accelerator which delivers 6 MV photons with an absorbed dose rate of 3 Gy min- 1 .
- FIG. 6 represents a matrix illustrating the correlations existing between the quantities of pATM present in the nucleus and the cellular cytoplasm of lymphoblasts originating from blood samples of individuals in the basal state (0 Gy - non-irradiated state), after 5 minutes and 10 minutes of repair (post-irradiation repair time).
- the correlation coefficient takes a value between 0 and 1. 0 means that there is no linear correlation between the two variables tested while 1 indicates that there is a relationship of proportionality between the two.
- the proportion of pATM proteins in the nucleus before irradiation and those after irradiation can not be correlated (see group A).
- the proportion of pATM proteins in the nucleus before irradiation is not correlated with the proportions of pATM proteins present in the cytoplasmic compartment, either in the non-irradiated basal state or at 5 or 10 minutes post irradiation.
- the correlation coefficient between 0Gy_nuc and 0Gy_cyto or 5mn_cyto or 10mn_cyto is close to 0.
- the quantities of pATM present in the nucleus at 5 min and 10 min post irradiation can be correlated with each other (see group B with a coefficient correlation close to 1).
- the amounts of pATM present in the cytoplasm in the basal state (0 Gy) at 5 min and 10 min post irradiation can be correlated together (see group C with a correlation coefficient close to 1).
- the threshold values Z, A, B, C, D and / or E can be defined according to the number of true or false positives tolerated, in particular by the practitioner, ie according to the sensitivity and the specificity required for the test for characterizing radiosensitivity, in particular for the test defining the radiosensitivity status.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1755262A FR3067467B1 (en) | 2017-06-13 | 2017-06-13 | RAPID PREDICTIVE METHOD FOR CHARACTERIZING THE RADIOSENSITIVITY AND / OR THE TISSUE REACTION OF AN INDIVIDUAL TO AN IRRADIATION |
FR1757779 | 2017-08-22 | ||
PCT/FR2018/051399 WO2018229439A1 (en) | 2017-06-13 | 2018-06-13 | Rapid predictive method for characterising the radiosensitivity and/or the risk of tissue toxicity of an individual to irradiation |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3685163A1 true EP3685163A1 (en) | 2020-07-29 |
Family
ID=63077887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18748969.5A Pending EP3685163A1 (en) | 2017-06-13 | 2018-06-13 | Rapid predictive method for characterising the radiosensitivity and/or the risk of tissue toxicity of an individual to irradiation |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3685163A1 (en) |
CA (1) | CA3073239A1 (en) |
WO (1) | WO2018229439A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022058472A1 (en) | 2020-09-17 | 2022-03-24 | Lxrepair | Method for predicting the risk of radiation-induced toxicity |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3005747A1 (en) * | 2013-05-15 | 2014-11-21 | Commissariat Energie Atomique | METHOD FOR BIODOSIMETRIC EVALUATION OF THE IRRADIATION DOSE RECEIVED BY AN INDIVIDUAL HAVING BEEN SUBJECTED TO IONIZING RADIATION |
JP6524108B2 (en) | 2014-02-17 | 2019-06-05 | ユニヴェルシテ クロード ベルナール リヨン 1 | Predictive methods for characterizing patient radiosensitivity and tissue response to therapeutic ionizing radiation |
FR3017624B1 (en) * | 2014-02-17 | 2018-03-23 | Universite Claude Bernard Lyon 1 | PREDICTIVE METHOD FOR CHARACTERIZING THE RADIOSENSITIVITY AND TISSUE REACTION OF A PATIENT TO THERAPEUTIC IONIZING RADIATION |
FR3017625B1 (en) * | 2014-02-17 | 2018-03-23 | Universite Claude Bernard Lyon 1 | PREDICTIVE METHOD FOR DETERMINING TISSUE RADIOSENSITIVITY |
FR3040176A1 (en) * | 2015-08-19 | 2017-02-24 | Neolys Diagnotics | PREDICTIVE METHOD OF EXCESS DOSE OF INDEXED CONTRAST PRODUCTS DURING RADIODIAGNOSTIC EXAMINATIONS AND EVALUATION OF EXCESS BIOLOGICAL DOSE |
-
2018
- 2018-06-13 CA CA3073239A patent/CA3073239A1/en active Pending
- 2018-06-13 EP EP18748969.5A patent/EP3685163A1/en active Pending
- 2018-06-13 WO PCT/FR2018/051399 patent/WO2018229439A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3073239A1 (en) | 2018-12-20 |
WO2018229439A1 (en) | 2018-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Malecova et al. | Dynamics of cellular states of fibro-adipogenic progenitors during myogenesis and muscular dystrophy | |
Lehmann et al. | Single-cell profiling reveals an endothelium-mediated immunomodulatory pathway in the eye choroid | |
Zhang et al. | Targeting nuclear receptor NR4A1–dependent adipocyte progenitor quiescence promotes metabolic adaptation to obesity | |
Borowik et al. | Skeletal muscle nuclei in mice are not post-mitotic | |
Jiao et al. | Microbial reconstitution improves aging-driven lacrimal gland circadian dysfunction | |
Hribkova et al. | Clozapine reverses dysfunction of glutamatergic neurons derived from clozapine-responsive schizophrenia patients | |
EP3387436B1 (en) | Rapid predictive method for characterising the radiosensitivity of a patient to irradiation with ionising radiation | |
Dokoshi et al. | Skin inflammation activates intestinal stromal fibroblasts and promotes colitis | |
Sellnow et al. | Striatal Nurr1 facilitates the dyskinetic state and exacerbates levodopa-induced dyskinesia in a rat model of Parkinson's disease | |
Zhou et al. | Transcriptome analysis of Klf15‑mediated inhibitory functions in a mouse deep venous thrombosis model | |
EP3685163A1 (en) | Rapid predictive method for characterising the radiosensitivity and/or the risk of tissue toxicity of an individual to irradiation | |
FR3067467B1 (en) | RAPID PREDICTIVE METHOD FOR CHARACTERIZING THE RADIOSENSITIVITY AND / OR THE TISSUE REACTION OF AN INDIVIDUAL TO AN IRRADIATION | |
US20140329322A1 (en) | Method of differentiating glioblastoma cells | |
Nelson et al. | Endothelial transcriptomics reveals activation of fibrosis-related pathways in hypertension | |
Maksour et al. | Innovations advancing our understanding of microglia in Alzheimer's disease: from in vitro to in vivo models | |
Liu et al. | R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts | |
Dutta et al. | Altered gut microbiome drives heightened pain sensitivity in a murine model of metastatic triple-negative breast cancer | |
Wei et al. | Comprehensive RNA-seq analysis of potential therapeutic targets of Gan–Dou–Fu–Mu decoction for treatment of Wilson disease using a toxic milk mouse model | |
Vasquez-Bolanos et al. | Transcriptional time course after rotator cuff tear | |
Mazuir et al. | Oligodendrocyte secreted factors shape hippocampal GABAergic neuron transcriptome and physiology | |
Ortega-Molina et al. | A mild increase in nutrient signaling to mTORC1 in mice leads to parenchymal damage, myeloid inflammation and shortened lifespan | |
Prata | Clonal dominance in bone marrow failure syndromes | |
Williams et al. | Circulation Research “In This Issue” Anthology | |
Zhang et al. | Integrative Bioinformatics Analysis Reveals the Key Molecular Players in Metastatic Adrenocortical Carcinoma | |
Mkrtchian et al. | Surgical Trauma in Mice Modifies the Content of Circulating Extracellular Vesicles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200602 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NEOLYS DIAGNOSTICS |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |